Payment overview · 2025
General Payments
$1,031.22
46 reported records · 13 companies
Healthcare provider profile · identity verified
Juan Cevallos, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · ZEPHYRHILLS, FL · NPI 1881705143
Verified facts
What the public records show
CMS Open Payments records show Juan Cevallos, MD received $1,031.22 in general payments during 2025 across 46 reported records.
GlaxoSmithKline, LLC. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Sunosi, Trelegy Ellipta, Xywav.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Tezspire by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Sunosi by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 960 claims for Trelegy Ellipta by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xywav by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Adempas by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $335.78 | 32.6% | 25 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $162.07 | 15.7% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $118.13 | 11.5% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $70.68 | 6.8% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $67.92 | 6.6% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $54.99 | 5.3% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $47.08 | 4.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.46 | 4.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.00 | 3.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.51 | 2.6% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $25.28 | 2.5% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $22.28 | 2.2% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $21.04 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $942.23 | 44 |
| Education | $88.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $201.55 | 15 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $162.07 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $134.23 | 10 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $118.13 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $70.68 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $67.92 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $47.08 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $26.51 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $21.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Sunosi sunosi |
2025 | Sunosi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 960 | exact normalized | Medicare Part D |
| XYWAV xywav |
2025 | Xywav | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
960 | 218 |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYWAV open payments reported associated product |
CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700 |
Xywav · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 1045 | 312 |
| Montelukast Sodium | Montelukast Sodium | 976 | 276 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 960 | 218 |
| Prednisone | Prednisone | 807 | 449 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 378 | 92 |
| Azithromycin | Azithromycin | 352 | 218 |
| Zolpidem Tartrate | Zolpidem Tartrate | 280 | 63 |
| Trazodone Hcl | Trazodone Hcl | 262 | 81 |
| Temazepam | Temazepam | 258 | 46 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 256 | 72 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 231 | 58 |
| Spiriva Respimat | Tiotropium Bromide | 228 | 50 |
| Azelastine Hcl | Azelastine Hcl | 210 | 91 |
| Clonazepam | Clonazepam | 207 | 48 |
| Doxycycline Hyclate | Doxycycline Hyclate | 205 | 145 |
| Fluticasone Propionate | Fluticasone Propionate | 204 | 89 |
| Symbicort | Budesonide/Formoterol Fumarate | 200 | 57 |
| Ipratropium Bromide | Ipratropium Bromide | 198 | 68 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 186 | 46 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 169 | 40 |
| Breo Ellipta | Fluticasone/Vilanterol | 144 | 34 |
| Alprazolam | Alprazolam | 141 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 139 | 31 |
| Eszopiclone | Eszopiclone | 136 | 31 |
| Fluconazole | Fluconazole | 108 | 48 |
| Famotidine | Famotidine | 104 | 37 |
| Furosemide | Furosemide | 98 | 37 |
| Cefdinir | Cefdinir | 97 | 74 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 92 | 19 |
| Lorazepam | Lorazepam | 87 | 26 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 82 | 21 |
| Omeprazole | Omeprazole | 82 | 24 |
| Mirtazapine | Mirtazapine | 73 | 19 |
| Gabapentin | Gabapentin | 70 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 70 | 23 |
| Potassium Chloride | Potassium Chloride | 66 | 18 |
| Modafinil | Modafinil | 65 | 20 |
| Theophylline Er | Theophylline Anhydrous | 58 | 21 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 55 | 17 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 54 | 17 |
| Doxepin Hcl | Doxepin Hcl | 54 | suppressed |
| Opsumit | Macitentan | 52 | suppressed |
| Tezspire | Tezepelumab-Ekko | 52 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 51 | 19 |
| Arnuity Ellipta | Fluticasone Furoate | 48 | 18 |
| Levofloxacin | Levofloxacin | 48 | 36 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 47 | suppressed |
| Clotrimazole | Clotrimazole | 45 | 14 |
| Bumetanide | Bumetanide | 43 | suppressed |
| Nystatin | Nystatin | 39 | 24 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | 16 |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 38 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 38 | suppressed |
| Dupixent Pen | Dupilumab | 37 | suppressed |
| Ambrisentan | Ambrisentan | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Ofev | Nintedanib Esylate | 34 | suppressed |
| Armodafinil | Armodafinil | 32 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 18 |
| Fasenra Pen | Benralizumab | 30 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 30 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Carvedilol | Carvedilol | 29 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 29 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 11 |
| Adempas | Riociguat | 25 | suppressed |
| Alvesco | Ciclesonide | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Tadalafil | Tadalafil | 24 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | suppressed |
| Losartan Potassium | Losartan Potassium | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 11 |
| Dulera | Mometasone/Formoterol | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Clarithromycin | Clarithromycin | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Lisinopril | Lisinopril | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 15 | suppressed |
| Desloratadine | Desloratadine | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Rifampin | Rifampin | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Pirfenidone | Pirfenidone | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Sunosi | Solriamfetol Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Xywav | Sodium,calcium,mag,pot Oxybate | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Orenitram Er | Treprostinil Diolamine | 12 | suppressed |
| Pulmicort Flexhaler | Budesonide | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Bosentan | Bosentan | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Remeron | Mirtazapine | 11 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,031.22 · 46 records | GlaxoSmithKline, LLC. | Arikayce, DUPIXENT, INSPIRE, LUMRYZ, NUCALA, Ohtuvayre, Prolastin-C Liquid, Sunosi, TRELEGY ELLIPTA, Vest Therapy Und, WINREVAIR, XYWAV | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Sunosi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error